Profound Medical Corp
TSX:PRN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
|
CN |
|
G
|
Grown Rogue International Inc
CNSX:GRIN
|
CA |
|
B
|
Brook Crompton Holdings Ltd
SGX:AWC
|
SG |
|
S
|
Smartgroup Corporation Ltd
ASX:SIQ
|
AU |
|
FB Financial Corp
NYSE:FBK
|
US |
|
Elevate Uranium Ltd
ASX:EL8
|
AU |
|
S
|
Setubandhan Infrastructure Ltd
NSE:SETUINFRA
|
IN |
|
Sensen Networks Ltd
ASX:SNS
|
AU |
|
Alithya Group Inc
TSX:ALYA
|
CA |
|
S
|
South West Petrovietnam Fertilizer and Chemicals JSC
VN:PSW
|
VN |
|
Beaver Group (Holding) Co Ltd
HKEX:8275
|
HK |
|
Brilliance China Automotive Holdings Ltd
HKEX:1114
|
HK |
|
K
|
Korea Electronic Power Industrial Development Co Ltd
KRX:130660
|
KR |
|
Kaleido Biosciences Inc
OTC:KLDO
|
US |
Profound Medical Corp
Research & Development
Profound Medical Corp
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Profound Medical Corp
TSX:PRN
|
Research & Development
-$20.6m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-18%
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Research & Development
-CA$2.6m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
|
|
MedMira Inc
XTSX:MIR
|
Research & Development
-CA$965.6k
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
3%
|
|
|
Aurora Spine Corp
XTSX:ASG
|
Research & Development
-$764.5k
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-25%
|
|
|
O
|
Ondine Biomedical Inc
LSE:OBI
|
Research & Development
-CA$9.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Conavi Medical Corp
XTSX:CNVI
|
Research & Development
-$13m
|
CAGR 3-Years
34%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
10%
|
|
Profound Medical Corp
Glance View
Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
See Also
What is Profound Medical Corp's Research & Development?
Research & Development
-20.6m
USD
Based on the financial report for Dec 31, 2025, Profound Medical Corp's Research & Development amounts to -20.6m USD.
What is Profound Medical Corp's Research & Development growth rate?
Research & Development CAGR 10Y
-18%
Over the last year, the Research & Development growth was -21%. The average annual Research & Development growth rates for Profound Medical Corp have been -12% over the past three years , and -18% over the past ten years .
